ArticleScientific reports2026
Spatiotemporal antimalarial drug resistance saturation and emerging artemisinin tolerance in western Kenya during a pilot multiple first-line treatment study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Emergence of partial resistance to artemisinin-based combination therapies (ACTs) threatens malaria control globally. This pilot multiple first-line treatment (MFT) for uncomplicated malaria study was conducted across three Western Kenya sites namely, Homa Bay County Mainland (intervention sites), Mfangano Island in Homa Bay County (intervention sites) and Migori County (control sites). The MFTs used were artemether plus lumefantrine (AL), dihydroartemisinin plus piperaquine (DHA + PIP), artesunate plus amodiaquine (AS + AQ) and artesunate plus pyronaridine (AS + PYD). The study was a serial cross-sectional analysis (September 2020–September 2022, extended to January 2024 for Mfangano Island) to characterize spatiotemporal resistance patterns following MFT deployment thus: (a) AL at baseline, then DHA + PIP for 8 months, followed by AS + AQ for 8 months, then AL for 8 months in Homa Bay County Mainland; (b) AL at baseline followed by AS + PYD for 36 months in Mfangano Island; (c) AL for 24 months in Migori County. Dried blood spots (n = 310) from malaria patients were analyzed for resistance markers (Pfdhfr, Pfdhps, Pfmdr1, Pfk13) using targeted amplicon deep sequencing. Deep sequencing generated 9,288,278 reads with mean complexity of infection 2.62 and 63% showing polyclonal infections. Core dhfr markers (N51I, S108N) showed saturation (100% non-wildtype), with emerging I164L detected at 12.2%. Dominant IRNI haplotype occurred in 93.7% of samples. For dhps, A437G and K540E reached fixation (100%), while S436H showed 33.4% prevalence. The mdr1 Y184F mutation demonstrated rapid temporal escalation in Homa Bay County Mainland (22.9% to 56.2%, P = 0.005). WHO-validated artemisinin resistance marker k13 A675V was detected (0.5%) and A578S, a k13 polymorphism not yet WHO-validated as a marker of artemisinin partial resistance, occurred in 7.8% of samples. Machine learning models achieved > 90% accuracy with genotype showing strongest predictive power. These findings suggest antimalarial resistance saturation in Western Kenya with emerging artemisinin resistance markers, indicating potential need for enhanced surveillance and alternative treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.